Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.286350
Mattia Algeri, Michele Massa, Daria Pagliara, Valentina Bertaina, Federica Galaverna, Ilaria Pili, Giuseppina Li Pira, Roberto Carta, Francesco Quagliarella, Rita M Pinto, Chiara Rosignoli, Barbarella Lucarelli, Maria G Cefalo, Emilia Boccieri, Francesca Benini, Francesca Del Bufalo, Marco Becilli, Pietro Merli, Gerhard Zugmaier, Franco Locatelli
Blinatumomab has remarkable efficacy in patients with relapsed/refractory (r/r) or measurable residual disease (MRD)-positive B-cell acute lymphoblastic leukemia (B-ALL). In many patients, blinatumomab treatment is followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, the influence of blinatumomab on HSCT outcomes in children and young adults (YA) remains to be fully elucidated. We conducted a single-center, retrospective analysis of patients given blinatumomab as last treatment before HSCT. Seventy-eight pediatric and YA patients were evaluated. With a median follow- up of 23.23 months, the 2-year disease-free (DFS) and overall survival (OS) probability were 72.2% and 89.2%, respectively, with a 2-year cumulative incidence of non-relapse mortality (NRM) of 2.6%. A trend toward improved 2-year DFS, but not OS, was noted in patients transplanted in first complete remission (CR1) (92.9%) compared to those in second or greater remission (CR2/3) (68.5%; P=0.18) due to a lower cumulative incidence of relapse (0% vs. 29.9%; P=0.05). Among CR2/3 patients, those receiving the sequential combination of inotuzumab and blinatumomab had a significantly lower cumulative incidence of relapse as compared to those who did not receive inotuzumab (9.5% vs. 40.4%; P=0.023). Relapse after HSCT occurred in 16 patients, all exhibiting CD19-positive blasts; ten of them received anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy and two inotuzumab as salvage therapy, leading to a 2-year post-relapse OS of 52.7%. Our results indicate that HSCT following blinatumomab in children and YA with B-ALL is highly effective, being associated with low NRM and not affecting the efficacy of subsequent salvage immunotherapies, including CAR T cells.
对于复发/难治(r/r)或可测量残留病(MRD)阳性B细胞急性淋巴细胞白血病(B-ALL)患者,Blinatumomab具有显著疗效。许多患者在接受blinatumomab治疗后,会进行异基因造血干细胞移植(HSCT)。然而,blinatumomab对儿童和年轻成人(YA)造血干细胞移植结果的影响仍有待全面阐明。我们对造血干细胞移植前最后一次接受blinatumomab治疗的患者进行了单中心回顾性分析。共有 78 名儿童和青年患者接受了评估。中位随访时间为23.23个月,2年无病生存率(DFS)和总生存率(OS)分别为72.2%和89.2%,2年非复发死亡率(NRM)的累积发生率(CI)为2.6%。与第二次或更多次缓解(CR2/3)患者(68.5%,P=0.18)相比,首次完全缓解(CR1)移植患者(92.9%)的2年DFS有改善趋势,但OS没有改善,原因是复发的CI较低(0% vs. 29.9%,P=0.05)。在CR2/3患者中,与未接受伊妥珠单抗治疗的患者相比,接受伊妥珠单抗和blinatumomab序贯联合治疗的患者复发CI显著较低(9.5% vs. 40.4%,p=0.023)。造血干细胞移植后复发的患者有16例,均表现为CD19阳性囊泡,其中10例接受了抗CD19嵌合抗原受体T细胞(CAR-T)疗法,2例接受了伊妥珠单抗作为挽救疗法,复发后2年的OS为52.7%。我们的研究结果表明,B-ALL患儿和YA接受blinatumomab治疗后进行造血干细胞移植非常有效,NRM较低,而且不会影响包括CAR-T细胞在内的后续挽救性免疫疗法的疗效。
{"title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation.","authors":"Mattia Algeri, Michele Massa, Daria Pagliara, Valentina Bertaina, Federica Galaverna, Ilaria Pili, Giuseppina Li Pira, Roberto Carta, Francesco Quagliarella, Rita M Pinto, Chiara Rosignoli, Barbarella Lucarelli, Maria G Cefalo, Emilia Boccieri, Francesca Benini, Francesca Del Bufalo, Marco Becilli, Pietro Merli, Gerhard Zugmaier, Franco Locatelli","doi":"10.3324/haematol.2024.286350","DOIUrl":"10.3324/haematol.2024.286350","url":null,"abstract":"<p><p>Blinatumomab has remarkable efficacy in patients with relapsed/refractory (r/r) or measurable residual disease (MRD)-positive B-cell acute lymphoblastic leukemia (B-ALL). In many patients, blinatumomab treatment is followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, the influence of blinatumomab on HSCT outcomes in children and young adults (YA) remains to be fully elucidated. We conducted a single-center, retrospective analysis of patients given blinatumomab as last treatment before HSCT. Seventy-eight pediatric and YA patients were evaluated. With a median follow- up of 23.23 months, the 2-year disease-free (DFS) and overall survival (OS) probability were 72.2% and 89.2%, respectively, with a 2-year cumulative incidence of non-relapse mortality (NRM) of 2.6%. A trend toward improved 2-year DFS, but not OS, was noted in patients transplanted in first complete remission (CR1) (92.9%) compared to those in second or greater remission (CR2/3) (68.5%; P=0.18) due to a lower cumulative incidence of relapse (0% vs. 29.9%; P=0.05). Among CR2/3 patients, those receiving the sequential combination of inotuzumab and blinatumomab had a significantly lower cumulative incidence of relapse as compared to those who did not receive inotuzumab (9.5% vs. 40.4%; P=0.023). Relapse after HSCT occurred in 16 patients, all exhibiting CD19-positive blasts; ten of them received anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy and two inotuzumab as salvage therapy, leading to a 2-year post-relapse OS of 52.7%. Our results indicate that HSCT following blinatumomab in children and YA with B-ALL is highly effective, being associated with low NRM and not affecting the efficacy of subsequent salvage immunotherapies, including CAR T cells.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"596-607"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.285066
Lily E A Scourfield, Amina Nardo-Marino, Thomas N Williams, David C Rees
Sickle cell disease (SCD) is one of the commonest severe inherited disorders in the world. Infection accounts for a significant amount of the morbidity and mortality, particularly in sub-Saharan Africa, but is relatively poorly studied and characterized. Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself. Those with more severe forms of SCD have functional asplenia from a very early age, which accounts for much of the morbidity in young children, particularly invasive infections from encapsulated bacteria including Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhi and meningococcal disease. Additionally, there are other defects in immune function in SCD, associated with anemia, tissue infarction and impaired adaptive immunity. Complications of infections in SCD include acute chest syndrome, acute painful episodes, osteomyelitis, meningitis, urinary tract infections, overwhelming sepsis and death. Viral infections cause significant morbidity, particularly severe anemia associated with parvovirus, and to a lesser extent other infections such as influenza and coronavirus disease 2019. The relationship between malaria and SCD is complicated and discussed in this review. Unlike many of the genetic risk factors for poor outcomes in SCD, it is theoretically possible to modify the risks associated with infections with established public health measures. These include the provision of vaccination, prophylactic antibiotics and access to clean water and mosquito avoidance, although current financial restraints and political priorities have made this difficult.
{"title":"Infections in sickle cell disease.","authors":"Lily E A Scourfield, Amina Nardo-Marino, Thomas N Williams, David C Rees","doi":"10.3324/haematol.2024.285066","DOIUrl":"10.3324/haematol.2024.285066","url":null,"abstract":"<p><p>Sickle cell disease (SCD) is one of the commonest severe inherited disorders in the world. Infection accounts for a significant amount of the morbidity and mortality, particularly in sub-Saharan Africa, but is relatively poorly studied and characterized. Patients with SCD have significant immunodeficiency and are more likely to suffer severe and life-threatening complications of infection, and additionally infections can trigger complications of SCD itself. Those with more severe forms of SCD have functional asplenia from a very early age, which accounts for much of the morbidity in young children, particularly invasive infections from encapsulated bacteria including Streptococcus pneumoniae, Haemophilus influenzae, Salmonella typhi and meningococcal disease. Additionally, there are other defects in immune function in SCD, associated with anemia, tissue infarction and impaired adaptive immunity. Complications of infections in SCD include acute chest syndrome, acute painful episodes, osteomyelitis, meningitis, urinary tract infections, overwhelming sepsis and death. Viral infections cause significant morbidity, particularly severe anemia associated with parvovirus, and to a lesser extent other infections such as influenza and coronavirus disease 2019. The relationship between malaria and SCD is complicated and discussed in this review. Unlike many of the genetic risk factors for poor outcomes in SCD, it is theoretically possible to modify the risks associated with infections with established public health measures. These include the provision of vaccination, prophylactic antibiotics and access to clean water and mosquito avoidance, although current financial restraints and political priorities have made this difficult.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"546-561"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.286157
Florentien E M In't Hout, Thessa N Scheele, Theresia M Westers, Canan Alhan, Carolien Duetz, Eline M P Cremers, Heleen A Visser-Wisselaar, Annelies Verbrugge, Dana A Chitu, Bert A Van der Reijden, Aniek O De Graaf, Arjan A Van de Loosdrecht, Joop H Jansen
{"title":"Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients.","authors":"Florentien E M In't Hout, Thessa N Scheele, Theresia M Westers, Canan Alhan, Carolien Duetz, Eline M P Cremers, Heleen A Visser-Wisselaar, Annelies Verbrugge, Dana A Chitu, Bert A Van der Reijden, Aniek O De Graaf, Arjan A Van de Loosdrecht, Joop H Jansen","doi":"10.3324/haematol.2024.286157","DOIUrl":"10.3324/haematol.2024.286157","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"772-776"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.285921
Mariana Nassif Kerbauy, Fernanda Agostini Rocha, Leonardo Javier Arcuri, Priscila Silva Cunegundes, Lucila Nassif Kerbauy, Clarisse Martins Machado, Andreza Alice Feitosa Ribeiro, Pinaki P Banerjee, Luciana Cavalheiro Marti, Nelson Hamerschlak
Post-transplant cyclophosphamide (PTCy) has contributed to the success of haploidentical hematopoietic stem cell transplantation (HSCT) and is also used in transplantation from matched donors. However, limited data on the immune reconstitution after this type of immunosuppression is available. We aimed to evaluate immune reconstitution after HSCT from unrelated donors, comparing anti-thymocyte globulin (ATG) and PTCy. Consecutive patients undergoing HSCT from unrelated donors and receiving either ATG or PTCy were prospectively included. Immune reconstitution analyses were performed by flow cytometry pre-transplant and on days 30, 60, 90, and 180 post-transplant. We included 36 patients, 20 in the ATG group and 16 in the PTCy group. In the early post-transplant period (day [d]+30), the ATG group showed a higher number of total lymphocytes, T, B, and natural killer (NK) cells compared to the PTCy group. However, at d+180, the PTCy group exhibited a higher number of B cells. On d+60 and d+90, the ATG group displayed higher number of NK cells CD56dim compared to the PTCy group, while on d+180, the PTCy group showed higher number of CD56-, CD16+, and, NKG2D+ NK cells. Naive CD4+, transition CD4+, and naive CD8+ T cells on d+60 were identified as risk factors for acute graft-versus-host disease grade 2-4, and a higher count of CD4+ memory cells on d+180 was identified as a risk factor for chronic graft-versus-host disease. In the context of unrelated allogeneic transplantation, immunosuppression with PTCy was associated with later B-, T- and NK-cell reconstitution compared to ATG.
{"title":"Immune reconstitution dynamics after unrelated allogeneic transplantation with post-transplant cyclophosphamide compared to classical immunosuppression with anti-thymocyte globulin: a prospective cohort study.","authors":"Mariana Nassif Kerbauy, Fernanda Agostini Rocha, Leonardo Javier Arcuri, Priscila Silva Cunegundes, Lucila Nassif Kerbauy, Clarisse Martins Machado, Andreza Alice Feitosa Ribeiro, Pinaki P Banerjee, Luciana Cavalheiro Marti, Nelson Hamerschlak","doi":"10.3324/haematol.2024.285921","DOIUrl":"10.3324/haematol.2024.285921","url":null,"abstract":"<p><p>Post-transplant cyclophosphamide (PTCy) has contributed to the success of haploidentical hematopoietic stem cell transplantation (HSCT) and is also used in transplantation from matched donors. However, limited data on the immune reconstitution after this type of immunosuppression is available. We aimed to evaluate immune reconstitution after HSCT from unrelated donors, comparing anti-thymocyte globulin (ATG) and PTCy. Consecutive patients undergoing HSCT from unrelated donors and receiving either ATG or PTCy were prospectively included. Immune reconstitution analyses were performed by flow cytometry pre-transplant and on days 30, 60, 90, and 180 post-transplant. We included 36 patients, 20 in the ATG group and 16 in the PTCy group. In the early post-transplant period (day [d]+30), the ATG group showed a higher number of total lymphocytes, T, B, and natural killer (NK) cells compared to the PTCy group. However, at d+180, the PTCy group exhibited a higher number of B cells. On d+60 and d+90, the ATG group displayed higher number of NK cells CD56dim compared to the PTCy group, while on d+180, the PTCy group showed higher number of CD56-, CD16+, and, NKG2D+ NK cells. Naive CD4+, transition CD4+, and naive CD8+ T cells on d+60 were identified as risk factors for acute graft-versus-host disease grade 2-4, and a higher count of CD4+ memory cells on d+180 was identified as a risk factor for chronic graft-versus-host disease. In the context of unrelated allogeneic transplantation, immunosuppression with PTCy was associated with later B-, T- and NK-cell reconstitution compared to ATG.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"640-650"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142285883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.286279
Cristina Florean, Manon Lernoux, Anne Lorant, Helene Losson, Guy Bormans, Michael Schnekenburger, Marc Diederich
{"title":"HDAC6 inhibitors sensitize resistant t(11;14) multiple myeloma cells to a combination of bortezomib and BH3 mimetics.","authors":"Cristina Florean, Manon Lernoux, Anne Lorant, Helene Losson, Guy Bormans, Michael Schnekenburger, Marc Diederich","doi":"10.3324/haematol.2024.286279","DOIUrl":"10.3324/haematol.2024.286279","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"784-790"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142390072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01DOI: 10.3324/haematol.2024.286338
Wellington F Silva, Haesook T Kim, Maria S Undurraga, Juan R Navarro-Cabrera, Victor Salinas, Pablo Muxi, Raul A M Melo, Ana Beatriz F Gloria, Katia B B Pagnano, Elenaide C Nunes, Rosane Isabel Bittencourt, Ninoska Rojas, Shirley M Q Truyenque, Ana Ilda Ayala-Lugo, Ana Carolina Oliver, Lorena L Figueiredo-Pontes, Fabiola Traina, Frederico Moreira, Evandro M Fagundes, Bruno K L Duarte, Analí Pamela Mora-Alferez, Percy Ortiz, Jose Luis Untama, Martin S Tallman, Raul C Ribeiro, Arnold Ganser, Richard James Dillon, Peter J M Valk, Miguel A Sanz, Bob Löwenberg, Nancy Berliner, Eduardo M Rego
{"title":"Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all-<i>trans</i> retinoic acid.","authors":"Wellington F Silva, Haesook T Kim, Maria S Undurraga, Juan R Navarro-Cabrera, Victor Salinas, Pablo Muxi, Raul A M Melo, Ana Beatriz F Gloria, Katia B B Pagnano, Elenaide C Nunes, Rosane Isabel Bittencourt, Ninoska Rojas, Shirley M Q Truyenque, Ana Ilda Ayala-Lugo, Ana Carolina Oliver, Lorena L Figueiredo-Pontes, Fabiola Traina, Frederico Moreira, Evandro M Fagundes, Bruno K L Duarte, Analí Pamela Mora-Alferez, Percy Ortiz, Jose Luis Untama, Martin S Tallman, Raul C Ribeiro, Arnold Ganser, Richard James Dillon, Peter J M Valk, Miguel A Sanz, Bob Löwenberg, Nancy Berliner, Eduardo M Rego","doi":"10.3324/haematol.2024.286338","DOIUrl":"10.3324/haematol.2024.286338","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"795-798"},"PeriodicalIF":8.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.3324/haematol.2025.287535
Bernhard Lammle
Not available.
{"title":"The third form of thrombotic thrombocytopenic purpura shows up again: what is it, does it even exist, how to find out? Comment on \"Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism\" and on \"The different faces of thrombotic thrombocytopenic purpura\".","authors":"Bernhard Lammle","doi":"10.3324/haematol.2025.287535","DOIUrl":"https://doi.org/10.3324/haematol.2025.287535","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-27DOI: 10.3324/haematol.2024.287107
Meghan Haney, Arfa Ashraf, Kelly E Lake, Lauren Strecker, Kasiani C Myers, Christopher Towe, Laura Walkup, Jason Woods, Stephanie L Edwards, Richard Cooper, Leslie E Lehmann, Gabriel Salinas Cisneros, Jason L Freedman, K Scott Baker, Erin Doherty, Margaret L MacMillan, Samuel B Goldfarb, Stella M Davies, Jane Koo, Transpire Groups
Not available.
{"title":"Community respiratory viruses are generally well-tolerated in hematopoietic stem cell transplant recipients: a brief report from the TRANSPIRE study.","authors":"Meghan Haney, Arfa Ashraf, Kelly E Lake, Lauren Strecker, Kasiani C Myers, Christopher Towe, Laura Walkup, Jason Woods, Stephanie L Edwards, Richard Cooper, Leslie E Lehmann, Gabriel Salinas Cisneros, Jason L Freedman, K Scott Baker, Erin Doherty, Margaret L MacMillan, Samuel B Goldfarb, Stella M Davies, Jane Koo, Transpire Groups","doi":"10.3324/haematol.2024.287107","DOIUrl":"https://doi.org/10.3324/haematol.2024.287107","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}